All information regarding prescription drugs on this site is intended only for doctors or pharmacists or nurses, authorized by local and national authorities to engage in their professions.

Kamada Ltd. is not responsible for any use made with this information, and use of it shall be the sole responsibility of the user.




Augmentation therapy for patients with emphysema secondary to congenital Alpha-1 Antitrypsin deficiency.

Active Ingredient: Alpha-1 Antitrypsin (Human)
Strength: 2%
Volume: 50 ml
Method of Administration: Ready-to-use solution for intravenous infusion

Product photo

About Alpha-1 Antitrypsin Deficiency (AAT Deficiency):

AAT deficiency is a hereditary condition that increases the risk of chronic obstructive pulmonary disease (COPD), especially emphysema and chronic bronchitis. People with alpha-1 antitrypsin deficiency are at risk of degeneration of lung function, which may significantly affect quality of life and life expectancy.

AAT protects the delicate tissues of the lung by inhibiting the destructive action of an enzyme called neutrophil elastase. Neutrophil elastase is released by white blood cells, and its primary function is to digest bacteria and other foreign particles in the lungs.
When a person with AAT deficiency inhales irritants or contracts a lung infection, the neutrophil elastase released in the lungs continues to act uncontrolled, leading do destruction of healthy lung tissue. This process may cause emphysema, leading to significant deterioration in lung function and even total destruction of lung tissue.

GLASSIA's is an augmentation therapy which helps to protect lung tissue from degeneration by increasing the AAT level.

For more information about AAT deficiency and Glassia®